Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01460641|
Recruitment Status : Completed
First Posted : October 27, 2011
Last Update Posted : September 7, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||21 participants|
|Official Title:||Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2018|
- Tumor stage change from Computed Tomography (CT) perfusion measurement [ Time Frame: 3 months ]
- Tumor perfusion as measured by perfusion CT. [ Time Frame: 1 year ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment.
- Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.
- No life expectancy restrictions.
- ECOG and Karnofsky Performance Status will not be employed.
- Patients with renal failure are ineligible for this study (GFR must be > 60)
- Ability to understand and willingness to sign a written informed consent document.
- Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment.
- No restrictions regarding use of other investigational agents.
- Patients with severe contrast allergy are ineligible.
- Patients who are pregnant or are trying to become pregnant are excluded from this study.
- Patients who are cancer survivors or HIV-positive will not be excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460641
|United States, California|
|Stanford University, School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Aya Kamaya||Stanford University|
|Responsible Party:||Aya Kamaya, Associate Professor of Radiology, Stanford University|
|Other Study ID Numbers:||
SU-10202011-8538 ( Other Identifier: Stanford University )
19224 ( Other Identifier: Stanford IRB )
|First Posted:||October 27, 2011 Key Record Dates|
|Last Update Posted:||September 7, 2018|
|Last Verified:||September 2018|
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases